Literature DB >> 11042682

High circulating proviral load with oligoclonal expansion of HTLV-1 bearing T cells in HTLV-1 carriers with strongyloidiasis.

A S Gabet1, F Mortreux, A Talarmin, Y Plumelle, I Leclercq, A Leroy, A Gessain, E Clity, M Joubert, E Wattel.   

Abstract

Adult T cell leukemia (ATLL) develops in 3 - 5% of HTLV-1 carriers after a long period of latency during which a persistent polyclonal expansion of HTLV-1 infected lymphocytes is observed in all individuals. This incubation period is significantly shortened in HTLV-1 carrier with Strongyloides stercoralis (Ss) infection, suggesting that Ss could be a cofactor of ATLL. As an increased T cell proliferation at the asymptomatic stage of HTLV-1 infection could increase the risk of malignant transformation, the effect of Ss infection on infected T lymphocytes was assessed in vivo in HTLV-1 asymptomatic carriers. After real-time quantitative PCR, the mean circulating HTLV-1 proviral load was more than five times higher in HTLV-1 carriers with strongyloidiasis than in HTLV-1+ individuals without Ss infection (P<0.009). This increased proviral load was found to result from the extensive proliferation of a restricted number of infected clones, i.e. from oligoclonal expansion, as evidenced by the semiquantitative amplification of HTLV-1 flanking sequences. The positive effect of Ss on clonal expansion was reversible under effective treatment of strongyloidiasis in one patient with parasitological cure whereas no significant modification of the HTLV-1 replication pattern was observed in an additional case with strongyloidiasis treatment failure. Therefore, Ss stimulates the oligoclonal proliferation of HTLV-1 infected cells in HTLV-1 asymptomatic carriers in vivo. This is thought to account for the shortened period of latency observed in ATLL patients with strongyloidiasis. Oncogene (2000) 19, 4954 - 4960

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11042682     DOI: 10.1038/sj.onc.1203870

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

1.  HTLV-1 propels untransformed CD4 lymphocytes into the cell cycle while protecting CD8 cells from death.

Authors:  David Sibon; Anne-Sophie Gabet; Marc Zandecki; Christiane Pinatel; Julien Thête; Marie-Hélène Delfau-Larue; Samira Rabaaoui; Antoine Gessain; Olivier Gout; Steven Jacobson; Franck Mortreux; Eric Wattel
Journal:  J Clin Invest       Date:  2006-04       Impact factor: 14.808

2.  Quantification of proviral load of human immunodeficiency virus type 2 subtypes A and B using real-time PCR.

Authors:  F Damond; D Descamps; I Farfara; J N Telles; S Puyeo; P Campa; A Leprêtre; S Matheron; F Brun-Vezinet; F Simon
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

Review 3.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

Review 4.  "Antivirals" in the treatment of adult T cell leukaemia- lymphoma (ATLL).

Authors:  Paul A Fields; Graham P Taylor
Journal:  Curr Hematol Malig Rep       Date:  2012-12       Impact factor: 3.952

Review 5.  Complicated and fatal Strongyloides infection in Canadians: risk factors, diagnosis and management.

Authors:  Sue Lim; Kevin Katz; Sigmund Krajden; Milan Fuksa; Jay S Keystone; Kevin C Kain
Journal:  CMAJ       Date:  2004-08-31       Impact factor: 8.262

6.  EBV promotes human CD8 NKT cell development.

Authors:  Yuling He; Ruijing Xiao; Xiang Ji; Li Li; Lang Chen; Jie Xiong; Wei Xiao; Yujuan Wang; Lijun Zhang; Rui Zhou; Xinti Tan; Yongyi Bi; Yan-Ping Jiang; Youxin Jin; Jinquan Tan
Journal:  PLoS Pathog       Date:  2010-05-20       Impact factor: 6.823

7.  High human T cell leukemia virus type-1(HTLV-1) provirus load in patients with HTLV-1 carriers complicated with HTLV-1-unrelated disorders.

Authors:  Daisuke Sasaki; Yuko Doi; Hiroo Hasegawa; Katsunori Yanagihara; Kunihiro Tsukasaki; Masako Iwanaga; Yasuaki Yamada; Toshiki Watanabe; Shimeru Kamihira
Journal:  Virol J       Date:  2010-04-28       Impact factor: 4.099

8.  Predictive markers for development of strongyloidiasis in patients infected with both Strongyloides stercoralis and HTLV-1.

Authors:  M Satoh; S Kiyuna; Y Shiroma; H Toma; A Kokaze; Y Sato
Journal:  Clin Exp Immunol       Date:  2003-09       Impact factor: 4.330

9.  High HTLV-1 proviral load, a marker for HTLV-1 associated myelopathy/tropical spastic paraparesis, is also detected in patients with infective dermatitis associated with HTLV-1.

Authors:  J Primo; I Siqueira; M C F Nascimento; M F Oliveira; L Farre; E M Carvalho; A L Bittencourt
Journal:  Braz J Med Biol Res       Date:  2009-07-03       Impact factor: 2.590

10.  MicroRNA miR-146a and further oncogenesis-related cellular microRNAs are dysregulated in HTLV-1-transformed T lymphocytes.

Authors:  Klemens Pichler; Grit Schneider; Ralph Grassmann
Journal:  Retrovirology       Date:  2008-11-12       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.